These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Regarding "recommendations for zoledronic acid treatment of patients with bone metastases". Parles K Oncologist; 2005 May; 10(5):304-5. PubMed ID: 15851780 [No Abstract] [Full Text] [Related]
43. Two cases of drug-induced orbital inflammatory disease. Ortiz-Perez S; Fernandez E; Molina JJ; Sanchez-Dalmau B; Navarro M; Corretger X; Olver JM Orbit; 2011 Jan; 30(1):37-9. PubMed ID: 21281079 [TBL] [Abstract][Full Text] [Related]
44. Orbital Inflammation Secondary to Zoledronic Acid, a Rare Presentation. Muruganandam M; Sandhu H J Clin Rheumatol; 2016 Oct; 22(7):384. PubMed ID: 27488454 [No Abstract] [Full Text] [Related]
45. Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases. Wongchuensoontorn C; Liebehenschel N; Wagner K; Fakler O; Gutwald R; Schmelzeisen R; Sauerbier S J Oral Maxillofac Surg; 2009 Jun; 67(6):1311-6. PubMed ID: 19446222 [No Abstract] [Full Text] [Related]
46. Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions. Jones SG; Dolan G; Lengyel K; Myers B Br J Haematol; 2002 Nov; 119(2):576-7. PubMed ID: 12406106 [No Abstract] [Full Text] [Related]
47. Zolendronic acid-induced retrobulbar optic neuritis: a case report. Brulinski P; Nikapota AD Clin Oncol (R Coll Radiol); 2013 May; 25(5):328-9. PubMed ID: 23357194 [No Abstract] [Full Text] [Related]
49. Post-surgery severe hypocalcemia in primary hyperparathyroidism preoperatively treated with zoledronic acid. Corsello SM; Paragliola RM; Locantore P; Ingraudo F; Ricciato MP; Rota CA; Senes P; Pontecorvi A Hormones (Athens); 2010; 9(4):338-42. PubMed ID: 21112866 [TBL] [Abstract][Full Text] [Related]
50. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?]. Ringe JD MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655 [No Abstract] [Full Text] [Related]
51. Comments on KDIGO clinical practice guidelines for bisphosphonate treatment of chronic kidney disease. Przedlacki J Kidney Int; 2010 Dec; 78(11):1186; author reply 1186. PubMed ID: 21076448 [No Abstract] [Full Text] [Related]
52. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. Swenson KK; Nissen MJ; Anderson E; Shapiro A; Schousboe J; Leach J J Support Oncol; 2009; 7(3):101-7. PubMed ID: 19507458 [TBL] [Abstract][Full Text] [Related]
53. Electrolyte abnormalities with zoledronic acid therapy. Sorscher SM Cancer J; 2002; 8(4):348; author reply 348-9. PubMed ID: 12184414 [No Abstract] [Full Text] [Related]
54. Serious ocular complications of zoledronate. Woo TC; Joseph DJ; Wilkinson R Clin Oncol (R Coll Radiol); 2006 Sep; 18(7):545-6. PubMed ID: 16969985 [No Abstract] [Full Text] [Related]
55. Hyperparathyroidism secondary to zoledronic acid infusion: case report. Sayin M; Yazici G Support Care Cancer; 2009 May; 17(5):469-70. PubMed ID: 19205753 [No Abstract] [Full Text] [Related]
57. Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer. Seth A; Anderson DP; Albiani DA; Barton JJ Can J Ophthalmol; 2009 Aug; 44(4):467-8. PubMed ID: 19606178 [No Abstract] [Full Text] [Related]